Olverembatinib
Myeloid Malignancy
Ascentage Pharma Group Inc.Small moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
29 Active assets in the Myeloid Malignancy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Mitoxantrone First Affiliated Hospital of Zhejiang University | Phase 3 | BBB |
Cytosin-Arabinosid First Affiliated Hospital of Zhejiang University | Phase 3 | BBB |
Cladribine University of Washington | Phase 2 | BBB |
Cyclophosphamide Prelude Therapeutics | Phase 3 | BB |
Venetoclax First Affiliated Hospital of Zhejiang University | Phase 3 | BB |
View all 49 →
Same molecule, other indications
Olverembatinib is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
66 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →